Uveitic macular oedema after treatment with vemurafenib

Acta Ophthalmol. 2015 Dec;93(8):e686-7. doi: 10.1111/aos.12678. Epub 2015 Feb 13.

Authors

Alex Fonollosa¹, Marina Mesquida², Alfredo Adan²

Affiliations

¹ Department of Ophthalmology, BioCruces Health Research Institute, Cruces University Hospital, University of the Basque Country, Barakaldo, Spain.
² Institut Clínic d'Oftalmologia, Hospital Clinic de Barcelona, University of Barcelona, Barcelona, Spain.

PMID: 25683228
DOI: 10.1111/aos.12678

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Agents / adverse effects*
Dexamethasone / administration & dosage
Drug Implants
Glucocorticoids / therapeutic use
Humans
Indoles / adverse effects*
Macular Edema / chemically induced*
Macular Edema / diagnosis
Macular Edema / drug therapy
Male
Melanoma / drug therapy*
Melanoma / secondary
Middle Aged
Prednisone / administration & dosage
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Sulfonamides / adverse effects*
Tomography, Optical Coherence
Triamcinolone Acetonide / therapeutic use
Uveitis / chemically induced*
Uveitis / diagnosis
Uveitis / drug therapy
Vemurafenib
Visual Acuity

Substances

Antineoplastic Agents
Drug Implants
Glucocorticoids
Indoles
Sulfonamides
Vemurafenib
Dexamethasone
BRAF protein, human
Proto-Oncogene Proteins B-raf
Triamcinolone Acetonide
Prednisone